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Abstract
Background: Assessing the quality of included trials is a central part of a systematic review. Many
check-list type of instruments for doing this exist. Using a trial of antibiotic treatment for acute
otitis media, Burke et al., BMJ, 1991, as the case study, this paper illustrates some limitations of the
check-list approach to trial quality assessment.
Results: The general verdict from the check list type evaluations in nine relevant systematic
reviews was that Burke et al. (1991) is a good quality trial. All relevant meta-analyses extensively
used its data to formulate therapeutic evidence. My comprehensive evaluation, on the other hand,
brought to the surface a series of serious problems in the design, conduct, analysis and report of
this trial that were missed by the earlier evaluations.
Conclusion: A check-list or instrument based approach, if used as a short-cut, may at times rate
deeply flawed trials as good quality trials. Check lists are crucial but they need to be augmented
with an in-depth review, and where possible, a scrutiny of the protocol, trial records, and original
data. The extent and severity of the problems I uncovered for this particular trial warrant an
independent audit before it is included in a systematic review.
Background
Clinical trials of poor quality continue to be reported in
virtually all medical fields [1-6]. Assessing the quality of a
trial is thereby essential, both for judging the reliability of
its conclusions, and for including it into a systematic
review. Due effort has, accordingly, been spent on devel-
oping appropriate instruments for the task. A 1999 over-
view found 25 different check lists for evaluating the
quality of a clinical trial [7-10].
Several concerns about trial quality check lists have, how-
ever, emerged. One, they vary appreciably in terms of the
number and types of components. Two, the weight they
accord to the components differs markedly. And three,
some lists have items unrelated to assessing bias, or gen-
eralizability of trial findings. The earlier use of quality
scores as weights in a meta-analysis, or for quality ranking
of trials is no longer advised. Recent work has sought to
identify the components of quality that often or strongly
affect trial outcomes. The findings show that adequate
allocation concealment is a key component for all types of
trials while the importance of the extent of blinding, even
when feasible, varies from one medical field to another
[10-17].
Systematic reviews now tend to use quality instruments
with a few key components that have been well studied.
The evaluation scheme noted in [18], page 58, which
includes four items (method of treatment assignment,
control of bias after assignment, blinding and outcome
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assessment), is one example. And, even with a good
scheme, the evaluation ought to be performed by two or
more independent, and when possible, blinded reviewers.
Any discord is resolved by discussion.
Despite these positive strides, quality assessment of trials
is still a nascent discipline. The sheer number of unevalu-
ated published and unpublished trials, the problem of
protocol deviation, the lack of standardized outcomes,
discrepancies between reported and actual conduct of tri-
als, and distortions induced by conflict of interest of
necessity render its current conclusions tentative. The for-
mulation of medical area specific quality instruments, and
including quality components relating to external valid-
ity, furthermore, have yet to receive due attention [16,19-
26].
There is also a methodologic matter that seems to have
escaped notice. In the process of developing instruments
with essential items, we may become oblivious to the fact
that this approach as such discretizes a complex construct.
It may hence foster an automated type of evaluation
whereby for each trial, a quality review consists of an
examination of the methods section, and a quick read of
the rest of the paper with the focus on noting the presence
or absence of relevant key words. There is then a danger
that, even with independent and blinded reviewers using
well regarded components of quality, such an approach
may at times generate a highly misleading assessment of
the quality of a clinical trial.
This papers aims to demonstrate, with the help of a case
study, that the danger is real, not just theoretical. The case
study pertains to the routine prescription of antibiotics for
acute otitis media (AOM) in children. This has been and
remains a common clinical practice. Yet, it has spawned
extensive controversy in the medical literature. The fact
that the clinical trials in that field had different selection
criteria, rules of diagnosis, and outcome measures also
contributed to the discord [27]. The quality of especially
the early trials is a key concern [28]. The trial of van
Buchem and colleagues [29], the related correspondence
[30,31], two semi-supportive editorials [32,33], and a
detailed critique [34], well illustrate the type and extent of
the discord that has long prevailed for treating this com-
mon pediatric ailment.
The first comprehensive quality review, based on 24
methodologic criteria, of antibiotic related trials for AOM
was published in 1992. Covering a total of 50 trials, it con-
cluded: "Many trials are methodologically flawed which makes
it diffcult to accept their result. In view of current controversy
on management of acute otitis media, well conducted placebo-
controlled trials are still needed." [35]. This assessment pre-
dates any systematic review for antibiotic treatment of
acute otitis media.
The specific case I study is the clinical trial of amoxycillin
for mild AOM in children, [36], published in 1991.
Referred to from now on as Burke et al., it was a double-
blind trial in which 114 children diagnosed with AOM
were randomized to amoxycillin, and 118 to a placebo. Its
message was unequivocal: "Use of antibiotic improves short
term outcome substantially and therefore continues to be an
appropriate management policy."
This trial was not covered in the comprehensive quality
review of acute otitis media trials in [35]. But, since its
publication, it has featured prominently in the systematic
reviews for AOM, where it has also been subjected to qual-
ity evaluation. In this paper, I compile these evaluations
from the nine relevant systematic reviews I identified. Fur-
ther, I show, through an in-depth but unstructured dissec-




Burke et al. evaluated the efficacy of amoxycillin for AOM
in children between the ages of 3 to 13 years. Unlike most
previous AOM trials, this was a multi-general practice
based study. To attain uniformity in diagnosis, evaluation
and follow up, training sessions for the participants were
held. Children were evaluated at the clinic (initially, day
8, one month, three months) and through two home vis-
its during the first week. Long term (one year) evaluation
was also done. Outcomes based on parental diaries, home
visits and in-clinic assessments were analyzed.
The main features of the trial, extracted mainly from the
Patients and Methods section of the paper, appear in
Table 1. The inclusion and exclusion criteria were speci-
fied, and a form for implementing them was devised. The
trial was sized for 80% power to detect a general effect. A
double blind, placebo-controlled design with an ade-
quately concealed randomization code was employed.
Data analysis methods were declared, and the main anal-
ysis was said to follow the intent-to-treat principle. The
rates of follow up in all the stages of the trial seem accept-
able. Hence, other than having many outcome variables,
it appeared to have had, in the main, the features of a
good quality trial. This was the verdict I arrived at through
a cursory check-list evaluation of Burke et al.
Evaluation in systematic reviews
The nine systematic reviews used different schemes to
assess trial quality. Two reviews used general quality crite-
ria like randomization for trial selection but did not men-
tion a further quality evaluation [37,38]. The sevenTrials 2009, 10:1 http://www.trialsjournal.com/content/10/1/1
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reviews with a formal quality evaluation used instruments
with three to eleven items. Three reviews gave a numeric
quality score, of which, one just reported the distribution
of scores [39-41]. Three reviews had independent evalua-
tors, and in one, they were also blinded [39,41,42]. One
review was an individual patient data meta-analysis with
full access to trial data, including that of Burke et al. The
data for all the included trials in this review were "thor-
oughly checked for consistency, plausibility, integrity of rand-
omization, and follow-up" [43].
Table 2 summarizes the quality evaluations of Burke et al.
in these reviews. (The details are in Additional file 1.) In
relation to internal validity, only three reviews had one or
two concerns for the trial [38,41,42]. These were: a possi-
ble lack of comparability of groups at baseline (crying), an
unclear outcome variable, and unspecified problems with
the follow up. These issues were noted in isolation, and
not pursued in any detail. One highly critical review noted
only one issue, and that in a superficial and biased way
[38]. Overall, it was deemed a good quality trial. The three
most recent systematic reviews including the individual
patient data meta-analysis, in particular, declared it a high
quality trial.
Student evaluation
The results of the comparative two-trial evaluation by the
students are in Table 3. Burke et al. was rated as a good or
excellent study by nearly 90% of the student respondents
while not a single student gave such a rating to the paper
[44]. In comparative terms, these evaluations were con-
sistent with those obtained from the systematic review
[40].
In-depth dissection
My comprehensive dissection of the paper, in contrast,
found an extensive number of design pitfalls, protocol
deviations, implementation glitches, data irregularities,
analytic flaws and reporting biases that were overlooked
or only partly noted in the three types of evaluations
above, including the three most recent systematic reviews.
These problems were serious enough to call into question
all the main findings of the trial. Implementation related
deficiencies affected baseline comparability, level of fol-
low up, extent of missing data, and other key facets of the
trial in an interrelated manner and introduced serious
biases in the emergent data.
The exact sources and details of my dissection of Burke et
al. are in Additional file 2. Each assertion made below is
Table 1: A check-list based quality assessment of Burke et al
Feature Assessment Feature Assessment
1. Study Question & Population Defined 12. Patient, Care Giver & Assessor Blinded
2. Treatment & Placebo Described 13. Informed Consent Obtained
3. Inclusion Criteria Specified 14. Statistical Method Specified
4. Exclusion Criteria Specified 15. Statistician Author* No
5. Main Outcome Measures Listed, Many 16. Intent to Treat Analysis Performed
6. Multipractice Study Yes 17. Baseline Characteristics Reported
7. Sample Size & Power Calculated 18. Groups Similar at Baseline Mostly
8. Missing Data & Losses Allowed For 19. Dropouts Reported Yes
9. Randomization Method Described 20. Dropout Rate Below 10%
10. Central Randomization Yes 21. Reasons for Dropouts Given
11. Randomization Concealment Adequate 22. Findings Support Conclusion 3 Apparently
Note: Assessment done by the author with criteria from [19]; * Statistician acknowledged.
Table 2: Quality assessments of Burke et al. in systematic reviews
Review Year NCT* Quality Internal Validity Problems
1. Lehnert [37] 1993 5 Good None Stated
2. Rosenfeld et al. [39] 1994 4 High None Stated
3. Del Mar et al. [40] 1997 8 10/11 None Stated
4. Froom et al. [53] 1997 7 Adequate None Stated
5. Cantekin [38] 1998 8 Not Good Baseline Comparability
6. Marcy et al. [41] 2001 6 4/5 Dropouts Description
7. Glasziou et al. [42] 2003 10 High Baseline Comparability, MO†
8. Rosenfeld [46] 2003 9 High None Stated
9. Rovers et al. [43] 2006 6 High None Stated
*NCT = Number of Controlled Trials; †MO = Misidentified OutcomeTrials 2009, 10:1 http://www.trialsjournal.com/content/10/1/1
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backed by requisite referencing, reasoning and/or compu-
tation given there. The reader is strongly advised to study
it with due care to judge the adequacy of evidence pro-
vided. Now, I summarize my major findings. The tables
cited in this subsection refer to the respective tables in
Burke et al.
Trial design
As described above, Burke et al. generally had a good
design. The three problems I found were: (i) the number
of main outcome variables, twenty, was excessive, (ii) the
designation of the set of main variables varied in different
parts of the paper; and (iii) the computation of sample
size had used abstract numbers, was in error by a margin
of about 20%, and did not allow for missing data or mul-
tiple outcomes.
Trial conduct
Evidence for major deviations from protocol at the base-
line visit, two home visits, and in-clinic visit on day 8 is
persuasive. These deviations produced serious biases in
the trial data. The medium and long term evaluations, on
the other hand, seem to have fared according to plan.
(i) At baseline, at least 12% of the cases were recruited in
violation of a key ethical and scientific exclusion criterion
(bulging ear drums) set for the trial; 16 of the 17 study
practices demonstrated poor record keeping; baseline data
were not collected fully, and in particular, no data on fever
at presentation-a key prognostic factor-were reported.
Besides low level of completeness, the baseline data also
had biased patterns. Thus, the proportions of cases with
bulging ear drums at the outset were significantly different
in the two groups. Also, 43% of the placebo, and 66% of
the antibiotic group either had missing data for crying or
were not crying at baseline (p < 0.001). The Cochrane
Review, [42], noted this difference as well, ascribing it to
a possible failure of randomization.
(ii) There was direct and indirect evidence that many of
the two planned home visits, especially the second one,
either did not occur or were appreciably delayed. This
affected the collection of historic baseline data, and the
delivery of the second parental diary scheduled for the
first home visit. It also impacted the weighing of medicine
bottles at both visits, and produced high and biased levels
of missingness for a key outcome, fever. Fever values were
missing for the first home visit for 24% of the antibiotic
and 23% of the placebo group; at the next home visit, the
respective levels were 55% and 41%, with a significantly
smaller proportion of the antibiotic group having data on
fever (p < 0.001).
Other anomalous patterns of missing data were also
observed. At each visit, researchers were to measure the
body temperature of the child, to record current pain and
weigh the medicine bottles during each visit. For the first
home visit, there were 3 missing values for pain, none for
analgesic use, but 52 missing values for fever. For the sec-
ond home visit, the anomalies were even more serious.
The authors only partly consider the problem with the
home visits. Thus, in the analysis of consumption of anal-
gesics, they reanalyzed the data to adjust for the "interval
between entry to trial and visit ...." But no details are given
and the adjustment was not done for any other variable.
Also, the impact on other aspects of the trial, like delivery
of the diaries and identification of treatment failure, was
not considered.
The anomalous patterns of missing data for these visits
raise the possibility that some of the researcher assessed
pain data may have been obtained by telephone, some
medicine bottles were later brought to the clinic, and
many visits did not actually occur. The rate (and/or tim-
ing), notably of the second visit, appear to have been
appreciably, if not significantly, higher (and/or earlier) for
the placebo group. This scenario puts all home visit data
into question. It may have contributed to earlier detection
and a higher declared rate of treatment failures in the pla-
cebo group. This was a key outcome, for which the issue
of timing is critical one (see below).
(iii) One striking feature of the in-clinic visit on day 8 is
the paucity of the data given. Of the 16 short term main
outcomes, only one (ear drum signs) directly derives from
evaluation by the physician at this visit. No data on fever
or pain assessment from this visit are given. Evidence indi-
cates that the treatment failures noted at this visit were
excluded from analysis, violating the protocol, and possi-
bly skewing the results in favor of antibiotic therapy (see
below).
Table 3: Student assessment: Burke et al. versus Halsted et al.
Quality Score
Study Very Bad Poor Acceptable Good Excellent Total
Halsted et al. [44] 3 4 4 0 0 11
Burke et al. 0 0 1 5 3 9
Note: 2 students had not read Burke et al.Trials 2009, 10:1 http://www.trialsjournal.com/content/10/1/1
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The nature of these problems raises a question about the
participation of the 48 trial doctors and other researchers
in the training sessions. This factor added to poor conduct
during the trial to produce deficient, biased and suspect
short term follow up data.
Data analysis
Four types of flawed data analytic methods were found:
(i) the survival curves for crying were flawed; (ii) some
missing data were coded as zero values giving incorrect
means and standard deviations; (iii) what were called
stratified analyses were actually partial sub-group analy-
ses; and (iv) the intent-to-treat analyses at times used only
about 50% of the subjects. Generally, these analytic errors
tended to produce results favoring antibiotic therapy. A
minor issue was that while all binary data comparisons
used risk ratios, they were repeatedly called odds ratios.
This particular mistaken identity error rarely occurs in the
medical literature [45].
Reporting style
The existence and severity of such problems (and others
described fully in Additional file 2) can be inferred only
by scrutinizing various sections of the paper with great
care and connecting different statements and data. For
example, baseline data are not tabulated but presented in
an unclear narrative manner. Outcomes not favoring anti-
biotic therapy do not receive due emphasis. Thus, pain
was the sole outcome with two distinct sources. Both con-
sistently showed equivalence between the treatment arms.
But these results were not only not stressed but dismissed
by an explanation that was not consistent with what the
authors state elsewhere. That about half of the cases had
missing data distributed in a biased manner for fever at
the second home visit is nowhere noted even though a sig-
nificant finding favoring antibiotic therapy was noted in
the Abstract. A similar situation pertained to the physician
evaluation on day 8, analyses relating to bulging ear
drums and other variables.
I examined the analysis of each of the twenty main out-
come variables in the light of the biases and methodologic
flaws I found. A statistically significant result favoring
antibiotic therapy was declared for five of the twenty main
outcomes. These were crying, fever at the second home
visit, analgesic use, treatment failure and school absence.
My reanalysis shows that these results do not hold up to
critical scrutiny. Below I summarize my reappraisal for
three of these variables.
Crying
At baseline, the crying status of roughly 43% of the pla-
cebo, and 66% of the antibiotic was either not known or
not crying. These data were, however, shown as survival
curves indicating "a real difference in outcome, rather than in
characteristic at entry." Consequently, as compared to pla-
cebo, antibiotic therapy was said to lower the mean dura-
tion of crying by about a day (p < 0.001), a p-value smaller
than for any other outcome.
But this analysis erroneously put zero as the duration of
crying for the cases who either were not crying at baseline
or had a missing value when comparing the two groups.
In terms of intent-to-treat analysis, this amounts to using
the best case scenario for the antibiotic. My estimate from
the data on those known to be crying at outset showed
that the median duration of crying for both groups was
about 1.5 days, and that the pattern of decline in rates of
crying in the two groups was quite similar. For crying, the
bias at baseline was thus compounded by a flawed and
biased analysis. Later, the authors state that some data
were reanalyzed to adjust for crying at onset. If all children
in both groups (with completed diaries) were crying at
outset, as clearly asserted in two earlier parts of the paper,
how such an adjustment can be done is not clear.
Fever
Fever, an important outcome for AOM, is not noted as a
main outcome in the Methods section but is declared as
such in Table 1[36]. Fever was not defined, no data on
fever at baseline or day 8 clinical visit are given, the home
visit fever data are missing at higher levels than for any
other variable, and the missingness pattern at the second
home visit is highly biased.
While the authors adjusted the analysis of analgesic use
up to the second home visit to account for the differing
times to the visit, such an adjustment was not done for
fever measured at the same visit. The intent-to-treat anal-
ysis for fever included only half the randomized subjects.
For fever at the second home visit, a significant difference
favoring antibiotic therapy was declared. As for crying,
data derived from biased conduct were analyzed in a
biased manner, yielding a significant finding for fever as
well.
Treatment failure
2% of the antibiotic group and 14% of the placebo were
declared as treatment failures (p = 0.001). Several con-
cerns bring this finding, repeatedly stressed in the paper,
into question. The first problem was definition: In the
Patients and Methods section, treatment failure is defined
without a time line. In the Short Term Outcome section,
the time line is specified as "on or before day 8." The data
in Table 1[36], however, exclude the day 8 in clinic visit,
and are only for treatment failures "during" the first week.
In particular, those showing "clear evidence of clinical dete-
rioration in one or both ears," as noted by the physician on
day at 8, and likely given a second line antibiotic, wereTrials 2009, 10:1 http://www.trialsjournal.com/content/10/1/1
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excluded. For this latter variable, no significant difference
between the two arms was found.
As detailed thoroughly in Additional file 2, varied evi-
dence indicates that this change of protocol reduced the
number of treatment failures and induced a bias in the
data. Bias in the timing and occurrence of home visits
with possibly higher rate or earlier timing of the visits in
the placebo groups may have led to a biased pattern and
earlier identification of treatment failures. The antibiotic
group failures detected later (on day 8) were not counted
in Table 1[36]. About 75% of the placebo group treatment
failures are vaguely classified as "Other non-resolution"
(Table 2[36]). Other cases like children withdrawn for
severe cough, diarrhea, rash or parental initiative, who
may been given a second line antibiotic, also seem not to
have been counted. My reanalysis, done to the extent pos-
sible from the data given, found a non significant p =
0.0933 between the treatment groups. Also, the baseline
imbalance between the two arms in terms of bulging ear
drums (an indicator for antibiotic therapy in the study)
confounded the finding on this outcome.
In a similar manner, the two other outcomes for which
statistically significant results were declared, namely, anal-
gesic consumption and absence from school, were
affected by biased patterns of home visits and missing
data, possible miscoding of missing data values, and lack
of baseline comparability.
Overall
These problems form a portion of a whole edifice serious
and minor problems detailed in Additional file 2. They are
not just reporting errors but reflect serious deficiencies
and biases in design, conduct and analysis. In the light of
these, and the totality of the information in the paper, it is
difficult to justify any of the main conclusions drawn. My
overall verdict is that Burke et al. is potentially a fatally
flawed trial. An independent audit is warranted before any
of its data and conclusions can be deemed credible.
Usage of Burke et al. data
Each systematic review of antibiotic versus placebo for
AOM with a meta-analysis has used the data from Burke
et al. In many, it was accorded a prominent role in terms
the number of outcomes contributed for analyses. I exam-
ined its contributions to the three most recent reviews,
[42,43,46]. The detailed results are in Additional file 1.
Below I give some of the highlights.
Rosenfeld (2003), with a total of nine trials, used the data
from Burke et al. in six of the seven meta-analyses compar-
ing antibiotic therapy with placebo or symptomatic ther-
apy. It is one of the three trials for which that was done.
Glasziou et al. (2004), the Cochrane Review with ten eli-
gible trials, meta-analyzed eight outcomes. Burke et al.
contributed to seven, and in four, it secured the highest
weight. Rovers et al. (2006), the sole individual patient
data meta-analysis had raw data from six trials, and
employed a composite main outcome based on fever and
pain at 3 to 7 days. Burke et al. accounted for 14% of the
total sample size. The outcomes from Burke et al. used in
these three reviews are shown in Table 4 in Additional file
1.
For the outcomes pain and/or fever, each of the three
reviews used the researcher based visit data, despite the
biased timings and high and biased levels of missing data
from the visits. Rovers et al. (2006) misrepresent the
researcher based data of Burke et al. as parental diary data.
They used visit 3 fever data of Burke et al. in their main
composite outcome despite the fact that they were miss-
ing (in a biased manner) for about half the cases. It is the
only trial in this review where the level of missingness for
a key outcome is inordinately high and biased, where no
data at all for a key baseline predictor (fever) are available,
and for which the data source is wrongly ascribed.
Rosenfeld (2003), the only review to meta-analyze treat-
ment failure, did not note the issue of inconsistent defini-
tions and misidentified outcomes. The Cochrane Review
used the data on adverse effects (vomiting, diarrhea and
rash) without taking double or triple counting, and the
longer time line, into consideration. The data on contral-
ateral pain used have the time line and faulty denomina-
tor problem as well. But it did draw attention to a possible
failure of randomization in the trial, though the implica-
tions were not pursued.
Overall, the three recent meta-analyses used the data from
Burke et al. in a manner that was oblivious to the multi-
plicity of serious problems connected with it. Even when
a problem was noted, the data were used anyways. Fur-
ther, some reviews introduced additional errors. Even
Rovers et al. (2006), with access to the raw data of Burke
et al., does not note or clarify any of the problems I
detected for it.
Conclusion
I note four limitations of my paper. First, it focused on
one study; the other studies in the field need scrutiny as
well. [34] assessed a single AOM trial; [6] assessed a single
trial in another field. I have gone further than both of
these papers in terms of design and methodologic issues.
Second, I mainly dealt with internal validity. Evaluation
of external validity is crucial [24,25] as well. Three, I was
the sole assessor in this endeavor. As a remedy, my find-
ings are given in extensive detail in the two additional files
accompanying this paper, so that my own work can be
evaluated thoroughly. And, four, my identification of rel-Trials 2009, 10:1 http://www.trialsjournal.com/content/10/1/1
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evant systematic reviews was by a hand search and did not
cover languages other than English. The treatment of
AOM has, for a long time, been surrounded by contro-
versy, and related trials and reviews have garnered exten-
sive publicity in the medical literature, and at times, in the
media as well. Thus, it is unlikely that a relevant review
has been missed.
To recapitulate, the check list-based evaluations in the sys-
tematic reviews, some by independent and blinded
reviewers, and my own check-list evaluation indicated
that Burke et al. had the main hallmarks of a good quality
trial. Published amidst mounting concerns about the
quality of AOM trials, it apparently not only anticipated
the call for better quality trials by Claessen et al. [35], but
also seemed to have addressed many of the design and
other types of weaknesses identified by them. The wide
usage of its findings in review papers also indicates the
regard accorded to it in the literature. Other review papers
and later trials have also referenced it in a positive light
(e.g. [27,47]). I have not come across any paper that has
raised and documented concerns serious enough to make
me question that verdict.
Yet, my detailed dissection revealed a wide chasm
between the image and reality. It showed that Burke at al.
is a seriously flawed and erroneously reported study. I
found good evidence for extreme baseline noncompara-
bility, deficient and biased short term follow up, nonran-
dom patterns of missing data, erroneous data analysis,
and biased interpretation. This sharp contrast between my
findings and the earlier evaluations has several implica-
tions.
The first relates to the methodology of quality assessment
of clinical trials for systematic reviews. Such reviews, espe-
cially of definitive and homogeneous trials, stand at the
top of the evidentiary hierarchy. They need to be per-
formed in an as thorough and meticulous a manner as
that required for a clinical trial. If one after another of the
systematic reviews in a field uncritically includes one or
more trials of dubious quality and validity, and magnifies
the problem by using their data inappropriately, then the
basis for regarding systematic review as a gold standard of
evidence begins to crumble [48,49].
For one particular issue, antibiotic versus symptomatic
therapy for AOM in children, and for one trial, Burke et
al., I have shown the existence of such a scenario. That its
flaws were not uncovered was due, I hold, not to the par-
ticular check list or instrument used but points to a possi-
ble shortcoming of the check-list approach to quality
evaluation as such.
Quality check lists are useful and essential, and the search
for key indicators of quality needs continued attention.
However, check lists need to be applied with care, and not
as a short-cut. A psychiatrist using a personality scale to
form an overall judgment of a patient would be remiss to
also not throughly evaluate the patient in person, and in
terms of other relevant records. In a similar fashion, each
trial in a review needs to be evaluated comprehensively.
There is a need to read the report and related papers with
care and a singularly critical lens, keeping both subject
matter related and general methodologic criteria in mind.
Authors should also be contacted for clarification, and, if
possible, the study protocol and original data obtained.
While that is a desired ideal, it has to be noted that com-
prehensive evaluation is a time consuming effort. Though
the type and scale of the problems I found for Burke et al.
could not have been detected other than by such an eval-
uation, the extent of the effort involved is indicated by the
fact that even a general reading of the paper by a class of
post-graduate physicians and seasoned researchers did
not bring its serious problems into relief. When these were
later explained to them, they were astonished by what
they had overlooked. There was, indeed, no short-cut
here; all short-cuts led into a blind alley. One referee of
my paper aptly described quality evaluation of trials as a
daunting task, and likened it to "a type of detective work that
aims to discover in particular what the authors of the trial
reports may have wished to conceal."
Nevertheless, a team performing a systematic review with
say, more than twenty trials, cannot be realistically
expected to devote the about three person-months I spent
to evaluate each trial. I propose three practical steps to at
least partly address this dilemma.
One
A systematic review team needs to include persons who
have intimately followed the literature on the topic at
hand. Their knowledge would help in the identification of
poor or good quality studies that a check-list evaluation
may overlook. They may or may not be a part of the group
of check-list evaluators. External assistance for this task
may also be sought. The basic goal should be to ensure
that each included trial report is thoroughly and critically
read by at least one person associated with the review.
Two
In addition to a check-list summary of quality, systematic
reviews should provide a two to three paragraph narrative
based synopsis of each trial, highlighting its strengths and
weakness. This can be posted on an associated web page.
Three
Systematic review needs to be viewed as a dynamic proc-
ess. Each review needs a mechanism through which cred-
ible concerns about any aspect of the review, including
quality evaluation, can be brought to bear into the proc-Trials 2009, 10:1 http://www.trialsjournal.com/content/10/1/1
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ess. It thereby becomes a dynamic mode of generating
knowledge not just in terms of incorporating new studies
but also for re-evaluation of studies done in the past. If the
authors of the review are obliged to respond to those con-
cerns and undertake needed rectifications, weeding out
poor quality studies and including ignored good quality
studies would be enhanced. The Cochrane Collaboration
has such a mechanism in place; though the extent to
which it has functioned effectively in practice needs to be
assessed.
The second implications of my paper relates specifically to
the trial of Burke et al. I am of the view that the totality of
the problems and the extent of bias revealed by my study
do suffice to denote it a potentially fatally flawed study.
An external audit of all aspects of the trial, and an inde-
pendent re-analysis of its data are needed. I also hold that
including its findings in a meta-analysis before the report
of such an inquiry are available is not warranted. My
paper, in addition, calls for a detailed evaluation of all
placebo-controlled studies of antibiotic treatment of acute
otitis media.
Another implication of my paper relates to journal peer
review. One goal of peer review is to detect major prob-
lems before they become ossified in print. My case study
illustrates a failure of this process. Also, no correspond-
ence relating to this trial was published. In the about one
and a half decades since this transpired, the issue of trial
quality has received greater attention, and journal editors
have taken many steps to improve peer-review. Unfortu-
nately, poor quality or deeply flawed trials continue to
appear in print, even in the major journals. As the recent
startling revelations surrounding several published trials
of COX-2 inhibitors in prominent journals show, contin-
ued vigilance on that front is in order [50].
The major task, however, is to prevent serious flaws in the
design, conduct and reporting of clinical trials. Transpar-
ency at all levels is the principal requirement here [51],
and registering trials, making protocols available, and
instituting a public repository of trial data constitute the
basic ingredients of this effort.
In conclusion: "Reflections on the details of a case [study]
allow one to draw broader lessons ..." [52], page 4. Like the
case study of [6], my case study has some ramifications
beyond its immediate purview. The severe limitations of
the check-list approach to quality evaluation for one spe-
cific trial I found implies that perhaps there is no short-cut
to trial quality evaluation. How often are poor quality tri-
als rated as good quality trials, and does that seriously dis-
tort the evidence emerging from systematic reviews? A
wider investigation of these questions is required.
Methods
Two main tasks were undertaken for this study. The first
task was to extract the quality assessments of Burke et al.
from systematic reviews. The criteria for an eligible review
were: One, it covered the comparison of antibiotic therapy
with placebo or symptomatic therapy for AOM in chil-
dren. Two, it was based on primary trials identified by a
form of systematic search. Three, its main aim was to sum-
marize the therapeutic evidence. It may or may not have
performed a meta-analysis. Four, it included the paper
Burke et al. And five, it was published in or before Decem-
ber 2006. Reviews which just summed up the findings
from other reviews were excluded. For updated reviews,
the most recent version was used. I identified the potential
reviews from a hand search of the English literature. Nine
systematic reviews published from 1993 to 2006 fulfilling
these criteria were selected [37-43,46,53].
From each review, I recorded the quality evaluation
method, the quality evaluation for Burke et al., and how
its data were used. I focused on issues pertaining to inter-
nal validity (selection, performance, detection, attrition,
analysis and reporting biases) as broadly described by
[16]. The information extracted is detailed in Additional
file 1: Burke et al. (1991) in nine systematic reviews.
The second main task was to perform an in-depth, com-
prehensive evaluation of Burke et al. This was done by
repeatedly and carefully reading the paper, performing a
section by section, and at times, sentence by sentence, dis-
section, and recording the relevant information. I checked
all the data for completeness, consistency and accuracy,
and assessed the reasoning, methods and conclusions in
various parts of the paper. Where possible, I reanalyzed
the data. At times, all potential datasets consistent with
other information provided were generated and analyzed.
During this process, I kept in mind the same quality com-
ponents relating to internal validity as those noted above
for systematic reviews. Other than that, I did not follow
any formal method. Indeed, the approach in such an exer-
cise will necessarily vary from trial to trial, and medical
field to medical field.
At the end, I formulated plausible explanations and an
overall perspective for the distinct problems I found.
Where feasible, flaws of reporting were distinguished
from the flaws in the design, conduct and analysis [23]. It
took about three months of focused work to complete my
in-depth review. The information extracted and the com-
plete picture I formed of this trial are in Additional file 2:
A detailed critique of Burke et al. (1991).
To complement these main tasks, two other activities were
undertaken. One, I performed a check list based qualityTrials 2009, 10:1 http://www.trialsjournal.com/content/10/1/1
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assessment of Burke et al. using Table 1 of Balk et al. [19]
as the template. This was completed before the in-depth
evaluation. The aim, in part, was to compare its conclu-
sions with those I found from the systematic reviews, and
in part, to provide an overall, standardized description of
the trial for this paper.
The second activity involved a class of medical researchers
and postgraduate students attending a course on evidence
based medicine conducted by me at the University of Oslo
in June 2006. They had had a day of lectures on the history
and basic principles of clinical trials in which several
examples of poor and high quality trials were given. They
were then required to read Burke et al. and another paper
(the first reported randomized trial which compared anti-
biotics with placebo for AOM [44]). At the start of the next
class session, they provided an overall quality evaluation
of the two papers on a five point scale (1 = very bad, 2 =
poor, 3 = acceptable, 4 = good, 5 = excellent). At this stage,
the use of specific scales or instruments to assess trial qual-
ity had not been discussed. Hence, this was not a check-
list based assessment. The aim here was to see whether the
students would spot problems with Burke et al. which the
systematic reviews had overlooked.
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